Recursion Pharmaceuticals (RXRX) Change in Acquisitions & Divestments (2021 - 2023)

Recursion Pharmaceuticals has reported Change in Acquisitions & Divestments for 3 years, with the latest figure at $480000.0 in Q3 2023.

• For the quarter ending Q3 2023, Change in Acquisitions & Divestments fell 99.22% year-over-year to $480000.0; the trailing twelve-month figure through Dec 2024 stood at $480000.0 (changed 0.0% YoY), and the FY2023 full-year result was $480000.0, down 99.79% from the prior year.
• Change in Acquisitions & Divestments for Q3 2023 stood at $480000.0, down from $61.5 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $147.6 million in Q1 2022, with the low at $480000.0 in Q3 2023.
• Historically, Change in Acquisitions & Divestments has averaged $60.1 million across 3 years, with a median of $61.5 million in 2022.
• The largest YoY upside for Change in Acquisitions & Divestments was 99.22% in 2023 against a maximum downside of 99.22% in 2023.
• Recursion Pharmaceuticals' Change in Acquisitions & Divestments stood at $69.2 million in 2021, then decreased by 11.05% to $61.5 million in 2022, then tumbled by 99.22% to $480000.0 in 2023.
• The last three Change in Acquisitions & Divestments figures came in at $480000.0 (Q3 2023), $61.5 million (Q3 2022), and $21.4 million (Q2 2022), per Business Quant data.